PRCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Procept Biorobotics Corp (PRCT) is not a good buy for a beginner investor with a long-term strategy at this moment. The stock is facing significant headwinds, including disappointing financial performance, bearish technical indicators, and negative sentiment from analysts and hedge funds. While there is potential for long-term growth, the current challenges and lack of positive catalysts make it a risky investment.
The technical indicators for PRCT are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 42.545, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 21.127, with resistance at 28.091. This suggests limited upward momentum in the short term.
The company has outlined 2026 financial targets, expecting revenue growth and a shift towards profitability. Additionally, the options market shows bullish sentiment with low put-call ratios.
The company missed Q4 2025 earnings and revenue expectations, reported a significant adjusted EBITDA loss for FY 2025, and is under investigation for potential securities fraud. Hedge funds are selling heavily, and analysts have significantly lowered price targets while expressing concerns about the company's ability to execute its strategy.
In Q4 2025, revenue increased by 11.94% YoY to $76.38M, but net income remained negative at -$29.85M, albeit improving by 58.28% YoY. EPS also improved to -0.53, up 51.43% YoY. However, gross margin dropped to 60.63%, down 5.27% YoY, indicating operational challenges.
Analysts are cautious, with multiple firms lowering price targets to $30 or below. Ratings are mixed, with some maintaining Buy ratings but others downgrading to Neutral or Underperform. Analysts cite concerns about market penetration, strategic execution, and profitability.
